American Heart Association Scientific Sessions 2020
News from AHA 2020 Virtual – What’s new from ODYSSEY OUTCOMES?
Benefit from alirocumab does not depend on triglyceride levels Are triglyceride (TG) levels associated with the risk for recurrent cardiovascular events in acute coronary syndrome (ACS) patients? Findings from this analysis from ODYSSEY OUTCOMES support baseline TG levels as an independent predictor of major adverse…
read more »
News from AHA 2020 Virtual: Novel PCSK9-targeted therapies
AZD8233: a potent PCSK9 synthesis inhibitor Data from a ‘first in human’ study suggest potential for AZD8233, a novel antisense oligonucleotide (1). This agent employs linkage with N-acetyl galactosamine (GalNAc) for efficient targeting of PCSK9 mRNA in hepatocytes to prevent the synthesis of PCSK9. In…
read more »
News from AHA 2020 Virtual: What’s new from FOURIER?
Evolocumab highly effective in patients with prior PCI Patients with atherosclerotic cardiovascular disease (ASCVD) and a history of percutaneous coronary intervention (PCI) are at very high risk for cardiovascular events. These individuals also benefit substantially from treatment with evolocumab on top of statin, as demonstrated…
read more »
News from AHA 2020 Virtual: Evinacumab in refractory hypercholesterolaemia
Evinacumab, a fully human monoclonal antibody inhibitor of angiopoietin-like 3 protein (ANGPTL3), given either intravenously or subcutaneously, more than halved LDL cholesterol when given on top of statin, ezetimibe and a PCSK9 inhibitor in patients with refractory hypercholesterolaemia. Earlier this year, evinacumab (15 mg/kg intravenously…
read more »
News from AHA 2020 Virtual: Weighing up STRENGTH
Final results from STRENGTH (Long-Term Outcomes Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia) not only show lack of cardiovascular benefit with this carboxylic acid omega-3 formulation in statin-treated patients with elevated triglycerides, but also highlight a potential…
read more »
